The discovery of new drugs has always been a challenging and expensive process. It involves extensive timeframes and significant costs, which have long highlighted the need for reform in this critical field. Despite previous efforts to accelerate drug discovery through computational methods, progress has remained limited.
Artificial intelligence (AI) has emerged as an exciting solution that shows great potential in revolutionizing AI for drug discovery and development. AI facilitates the identification of optimal drug candidates, provides unprecedented insights into various diseases, and effectively manages extensive patient datasets. These capabilities are driving transformative change across the pharmaceutical landscape.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
